Nature: Developing personalized theranostic solutions

In the News, News

Clarity Pharmaceuticals was featured in Nature’s MedTech Dealmakers, a publication dedicated to exploring the dealmaking trends of the growing medical technology industry. The article discussed Clarity’s most recent developments and highlighted the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine. Read the full article here: https://biopharmadealmakers.nature.com/users/37997-clarity-pharmaceuticals/documents/16507-clarity-pharmaceuticals-medtech-2017 Or as a PDF http://www.claritypharmaceuticals.com/wp-content/uploads/2017/05/Clarity-Pharmaceuticals-MedTech-2017.pdf…

Biotech dispatch

Biotech Dispatch: Clarity establishes European subsidiary

In the News, News

Clarity Pharmaceuticals was featured in Biotech Dispatch, a publication dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector. The article highlighted Clarity’s expansion to Europe through the establishment of a subsidiary Company in Liège, Belgium, and the awarding of a local grant. Read the full article here: http://biotechdispatch.com.au/clarity-establishes-european-subsidiary/#sthash.vlRgoIh5.VDwTViUT.dpbs Or as…

Elsevier article

Elsevier – Start-Up Spotlight: Clarity Pharmaceuticals

In the News, News

Clarity Pharmaceuticals was featured in Pharma R&D Today by Elsevier, a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals. “We believe in personalized medicine and the development of new therapies that are more effective and have less side effects. At Clarity, we recognized that radiopharmaceuticals have this potential…

European union grant

Clarity awarded EUR950,000 Belgium government grant to develop vulnerable plaque diagnostic

News, Press Releases

Sydney, Australia 11 August 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, including cancer and heart disease, has been awarded a Belgium government grant of approximately EUR950,000 under the Wallonia region COOTECH program. The grant is funded by the European Union and the Directorate General for Economy, Employment…

CRC Grant

Clarity awarded $2.5 million CRC-Projects Grant

News, Press Releases

Sydney, Australia 27 June 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious diseases, especially cancer, has been awarded a Cooperative Research Centres Projects (CRC-P) grant. This grant is part of the Australian Government’s Cooperative Research Centres Programme. The grant, valued at $2,513,000, will fund the extension of Clarity’s capabilities of…

ANSTO provides groundwork for promising new nuclear medicine

News

Building on comprehensive work of a former ANSTO researcher Prof Suzanne Smith, Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has progressed its lead product SARTATE™ from the lab into the clinic for treatment of a range of cancers including neuroendocrine tumours and childhood cancers. The product, a promising molecular imaging…

Clarity News article

Home-grown biotech innovator, Clarity Pharmaceuticals, raises AU$2 million to fight cancer

News, Press Releases

Clarity Pharmaceuticals pioneers world first use of copper radioisotopes for diagnosis, dosimetry and treatment of cancer Sydney, Australia, 24 May 2016 – Clarity Pharmaceuticals, an emerging Australian biotech company specialising in the treatment of serious disease, has raised AU$2 million to develop its clinical pipeline using its proprietary drug targeting technology. The investment round includes…